Welcome to our dedicated page for Remsleep Holding news (Ticker: RMSL), a resource for investors and traders seeking the latest updates and insights on Remsleep Holding stock.
REMSleep Holdings, Inc. (RMSL) specializes in developing innovative CPAP interface solutions to improve sleep apnea treatment outcomes. This page serves as the definitive source for verified company news and announcements, providing stakeholders with timely updates on product developments, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find curated information spanning FDA clearances, clinical study results, partnership announcements, and market expansion efforts. The resource emphasizes REMSleep's commitment to advancing CPAP therapy through its flagship DELTAWAVE Nasal Pillows System, engineered to address critical patient compliance challenges.
Regular updates cover essential developments including manufacturing advancements, distribution network growth, and sleep health research collaborations. All content is vetted for accuracy and relevance to support informed decision-making while maintaining strict compliance with financial disclosure standards.
Bookmark this page for direct access to REMSleep's evolving narrative in respiratory care innovation. For comprehensive understanding of the company's market position, cross-reference updates with SEC filings and official investor communications.
RemSleep Holdings (OTCQB: RMSL) has outlined key goals for 2023 in a recent update from CEO Tom Wood. The company aims for a successful FDA 510K submission for its DeltaWave CPAP mask by mid-March. Hiring Judy Strzepek has bolstered regulatory efforts, and the company is optimistic about the quicker path for future product approvals. RemSleep plans to enhance its sales strategy while addressing inventory challenges caused by market recalls. Additionally, promising internal results for new masks could lead to competitive advantages in treating COPD and CHF in sleep apnea patients.
Tampa, FL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- RemSleep Holdings (OTCQB: RMSL) announced the commencement of final battery testing for its DeltaWave mask, expected to take 14-18 weeks. The delay is due to a GXP analysis issue regarding ISO testing protocols, necessitating new inventory and packaging. The company is also seeking patent rights for new masks and investigating clinical trial parameters for COPD and CHF treatment. CEO Tom Wood acknowledged setbacks and emphasized the importance of following proper protocols.
RemSleep Holdings (OTCQB: RMSL) announced that its common shares will start trading on the OTCQB Market as of July 27, 2022. This tier upgrade positions RemSleep among companies meeting high financial standards and regulatory compliance. CEO Tom Wood expressed optimism about expanding the shareholder base and enhancing transparency with investors. RemSleep manufactures medical devices for treating obstructive Sleep Apnea, leveraging over 30 years of CPAP experience. Investors can find real-time financial data and quotes on OTC Markets.
RemSleep Holdings (OTC Pink: RMSL) appointed Judy Strzepek as Senior Director for Regulatory Compliance to oversee FDA submissions for its DeltaWave Nasal Pillow Mask. The company has engaged a new regulatory testing firm with expertise in class II medical devices to support this process. Both appointments aim to enhance the company's compliance and expedite the FDA 510k submission. Challenges faced during the pandemic highlighted the necessity for specialized regulatory guidance. RemSleep is optimistic about achieving FDA clearance with their improved infrastructure.
RemSleep Holdings Inc. (OTC PINK: RMSL) issued a correction regarding its previous announcement about receiving approval for OTCQB uplisting. The company clarified that no confirmation has been given by OTC Markets and all inaccurate statements have been retracted. RemSleep apologized to shareholders and the OTC Markets Group for the misinformation. The firm focuses on innovative medical devices for obstructive Sleep Apnea treatment.
RemSleep Holdings (OTC PINK: RMSL) announced its uplisting to OTCQB® status, enhancing investor benefits including improved reporting standards and greater access to analyst coverage. This uplisting is expected to increase liquidity, market visibility, and shareholder value. CEO Tom Wood emphasized the significance of this milestone, pointing to upcoming FDA filings for their DeltaWave Nasal Pillow Mask and plans for additional CPAP devices. The company aims to transition from a pre-revenue state to a profitable public entity.
RemSleep Holdings Inc (OTC PINK: RMSL) recently addressed shareholders regarding its S-1 filing dated June 15, 2022. The company clarified that the S-1 was precautionary, aimed at providing a safety net amid rising inflation and economic challenges, not an immediate necessity. They reaffirmed goals of increasing revenue from CPAP agreements, obtaining FDA approval for the DeltaWave Nasal Pillow Mask, and expanding their product line. The company has decided to terminate the S-1 filing and has no current plans to raise capital or increase share counts.
